BRAF V600D

One of these patients who had 100% homology began treatment with cladribine monotherapy and relapsed at 20 months, while the other 4 had initial treatment containing rituximab and have not relapsed. While those with BRAF V600 mutations might be candidates for BRAF inhibition, those with other BRAF mutations represent an opportunity for development of other specific inhibitors, not only for HCL/HCLv, but also for other malignancies. We believe more patients with HCL should be tested for non-V600E BRAF mutations.

P2, N=26, Active, not recruiting, University Health Network, Toronto | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024

P2, N=35, Active, not recruiting, National Cancer Institute (NCI)

P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2023 --> Apr 2025

P2, N=26, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 | Recruiting --> Active, not recruiting

The Idylla BRAF Mutation Assay is a highly reliable and sensitive platform for detecting BRAF pathogenic variants in codon 600 in malignant melanoma. The test can be performed in less than two hours, significantly improving turnaround time, thus allowing faster time to treatment.

P=N/A, N=3, Terminated, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Oct 2024 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Jul 2023; low accrual and lack of funds

A case of metastatic cutaneous melanoma to the choroid with choroidal elevation and subretinal exudation to the fovea, for which treatment with dabrafenib/trametinib was initiated. Rapid and complete resolution of choroidal metastasis and the associated subretinal exudation after initiation of combined targeted therapy was seen, without any ocular side effects.

P=N/A, N=8, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: May 2023 --> Oct 2023

P2, N=19, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 19

P1/2, N=50, Completed, Abramson Cancer Center of the University of Pennsylvania | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Oct 2021 | Trial primary completion date: Oct 2024 --> Oct 2021

P2, N=26, Recruiting, University Health Network, Toronto | Trial completion date: Sep 2021 --> Dec 2023 | Trial primary completion date: Sep 2021 --> Dec 2023

Therapy with ipilimumab and nivolumab was initiated and paused after 2 cycles because of pronounced arthralgia...Symptom relief was achieved after NSAID and prednisolone administration...If a BRAFV600D mutation was detected, the patient opted for therapy with dabrafenib and trametinib... Our cases demonstrate that neoadjuvant therapies can reduce the risk of surgery by reducing the tumor mass. The pathological treatment response can be decisive for the recommendation of postoperative therapy. The duration of the subsequent therapy was chosen individually according to the clinical response; standardized recommendations are not yet possible.

P2, N=26, Recruiting, University Health Network, Toronto | Active, not recruiting --> Recruiting

Even with residual tumor, all patients are alive (median follow-up, 83 months; 19-139). This study further supports DIG as another MAPK pathway-driven neuroepithelial tumor, thus expanding potential treatment options for tumors not amenable to surgical cure, and suggests that DIG is a microglia/macrophage-rich neuroepithelial tumor with frequent low driver mutation allele frequencies.

P2, N=26, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting

P=N/A, N=658, Completed, Genentech | N=1000 --> 658